NewsDialy
A breast cancer drug failed its largest clinical test, a result that could limit how widely the medicine is prescribed.
First-line therapy is the term for the initial drug doctors try after a patient's cancer advances, before other options are substituted or added.
That is what AstraZeneca's camizestrant was being tested for: the drug, taken as a pill alongside another medicine, did not keep cancer from progressing longer than standard care in the SERENA-4 trial, AstraZeneca said Friday.
What the trial was testing SERENA-4 enrolled patients with ER-positive, HER2-negative advanced breast cancer who had not yet received systemic therapy for their advanced disease.
Keep reading